Українська Русский English

ISSN 2522-9028 (Print)
ISSN 2522-9036 (Online)
DOI: https://doi.org/10.15407/fz

Fiziologichnyi Zhurnal

is a scientific journal issued by the

Bogomoletz Institute of Physiology
National Academy of Sciences of Ukraine

Editor-in-chief: V.F. Sagach

The journal was founded in 1955 as
1955 – 1977 "Fiziolohichnyi zhurnal" (ISSN 0015 – 3311)
1978 – 1993 "Fiziologicheskii zhurnal" (ISSN 0201 – 8489)
1994 – 2016 "Fiziolohichnyi zhurnal" (ISSN 0201 – 8489)
2017 – "Fiziolohichnyi zhurnal" (ISSN 2522-9028)

Fiziol. Zh. 2016; 62(3): 54-59


BONE REGULATORY MECHANISMS DESTRUCTION IN EXPERIMENTAL CHRONIC KIDNEY DISEASE

S.B. Pavlov, M.V. Kumechko, O.B. Litvinova, N.M. Babenko, A.V. Goncharova

    Kharkiv Medical Academy of Postgraduate Education
DOI: https://doi.org/10.15407/fz62.03.054

Abstract

The aim of our study was to investigate the role of intercellular mediators – interleukin-1 receptor antagonist (IL-1 RA), interleukin-17 (IL-17), receptor activator of nuclear factor kB ligand (RANKL) and osteoprotegerin in the mechanisms of metabolic regulation of renal and bone tissue on model of violations of bone remodeling in chronic kidney disease (CKD). It was found a significant increase in the content of cytokines IL-1 RA (4,207 ± 0,546 pg/ml), IL-17 (33,944 ± 0,938 pg/ ml), osteoprotegerin (28,338 ± 1,223 pg/ml) and RANKL (0,184 ± 0,018 pmol/l) in the serum of animals in violation of bone remodeling in CKD compared with the contents of the studied cytokines in animals in the control group (2,529 ± 0,132 pg/ml, 28,166 ± 0,526 pg/ml, 21,588 ± 0,763 pg/ml and 0,131 ± 0,006 pmol/l, respectively) (P<0.05). The obtained correlations reflect the relationship between regulation of bone remodeling and the development of inflammation in CKD. The imbalance between pro- and anti-inflammatory cytokine plays an important role both in the development of CKD and in processes of bone remodeling.

Keywords: bone remodeling; chronic kidney disease; pro- and anti-inflammatory cytokines.

References

  1. Kraydashenko OV, Dolinnaya MA. The role of biomarkers in the assessment of the nature of kidney damage in patients with hypertension. Clin Nephrol 2014; 3: 23–5. [Russian].
  2.  
  3. Kairaitis LK, Harris DC. Tubular-interstitial interactions in proteinuric renal diseases. Nephrology. 2001; 6: 198–207. CrossRef  
  4. Gal-Moscovici A, Sprague SM. Bone health in chronic kidney disease mineral and bone disease. Adv Chronic Kidney Dis. 2007; 14 (1): 27–36. CrossRef PubMed
  5.  
  6. Yamashita T, Takahashi N, Udagawa N. New roles of osteoblasts involved in osteoclast differentiation. World J Orthop. 2012; 3 (11): 175–81. CrossRef PubMed PubMedCentral
  7.  
  8. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006; 441: 235–8. CrossRef PubMed
  9.  
  10. Zwerina K, Koenders M, Hueber A, Marijnissen RJ, Baum W, Heiland GR, Zaiss M, McLnnes I, Joosten L, van den Berg W, Zwerina J, Schett G. Anti IL-17A therapy inhibits bone loss in TNF-α-mediated murine arthritis by modulation of the T-cell balance. Eur J Immunol. 2012; 42 (2): 413–23. CrossRef PubMed
  11.  
  12. Kondakov II, Topchii II, Kirienko OM. Influence of glicerol on functional-morphological indicators of kidneys at modelling renal insufficiency in rats. Ukr J Nephrol Dialysis. 2013; 3 (39): 14–20. [Ukrainian].
  13.  
  14. Sarkisov D.S., Perova J.L. Microscopic technique. M: Medicine; 1996. [Russian].
  15.  
  16. Podkovkin V.G., Ivanov D.G., Ivanov G.A. The effect of magnetic field on the bone tissue status in rats with high level bone resorption. Adv Curr Nat Sci. 2008; 7: 13–6. [Russian].
  17.  
  18. Moss RB, Moll T, El-Kalay M, Kohne C, Soo Hoo W, Encinas J, Carlo DJ. Th1/Th2 cells in inflammatory disease states: therapeutic implications. Expert Opin Biol Ther. 2004; 4 (12): 1887–96. CrossRef PubMed
  19.  
  20. Kim JH, Jin HM, Kim K, Song I, Youn BU, Matsuo K, Kim N. The Mechanism of Osteoclast Differentiation Induced by IL-1. The Journal of Immunology. 2009; 183 (3): 1862–70. CrossRef PubMed
  21.  
  22. Lambert C, Oury C, Dejardin E, Chariot A, Piette J, Malaise M, Merville MP, Franchimont N. Further Insights in the Mechanisms of Interleukin-1β Stimulation of Osteoprotegerin in Osteoblast-Like Cells. Journal Of Bone And Mineral Research. 2007; 22 (9): 1350–61. CrossRef PubMed
  23.  
  24. Lee YM, Fujikado N, Manaka H, Yasuda H, Iwakura Y. IL-1 plays an important role in the bone metabolism under physiological conditions. International Immunology. 2010; 22 (10): 805–16. CrossRef PubMed
  25.  
  26. Moschen AR, Kaser A, Enrich B, Ludwiczek O, Gabriel M, Obrist P, Wolf AM, Tilg H. The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss. Gut. 2005; 54 (4): 479–87. CrossRef PubMed PubMedCentral
  27.  
  28. Nascimento M.M., Hayashi S.Y., Riella M.C., Lindholm B. Elevated levels of plasma osteoprotegerin are associated with all-cause mortality risk and atherosclerosis in patients with stages 3 to 5 chronic kidney disease. Braz J Med Biol Res. 2014; 47 (11): 995–1002. CrossRef PubMed PubMedCentral
  29.  
  30. Tunyogi-Csapo M, Kis-Toth K, Radacs M, Farkas B, Jacobs JJ, Finnegan A, Mikecz K, Glant TT. Cytokine-controlled RANKL and osteoprotegerin expression by human and mouse synovial fibroblasts: fibroblast-mediated pathologic bone resorption. ArthritisRheum. 2008; 58 (8): 2397–408. CrossRef PubMed
  31.  

© National Academy of Sciences of Ukraine, Bogomoletz Institute of Physiology, 2014-2019.